Practical advice for management of inflammatory bowel diseases patients during the COVID‐19 pandemic: World Endoscopy Organization Statement

Neumann, Helmut; Emura, Fabián; Bokemeyer, Bernd; Guda, Nalini M.; Tajiri, Hisao; Matsumoto, Takayuki; Rubin, David T.

doi:10.1111/den.13712

Cited by 12 publications

(11 citation statements)

References 23 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fever and respiratory symptoms are the most common symptoms in COVID-19 [12]. In general, gastrointestinal symptoms have been reported in patients with COVID-19 in around 15% of affected patients, with diarrhea, nausea, vomiting, and anorexia being the most common symptoms.…”

Section: Covid-19 In Ibd: Clinical Featuresmentioning

confidence: 99%

“…The world health organization (WHO) interim guidance on clinical management of COVID-19 (updated 27 May 2020) [25] recommends that given the lack of effectiveness and possible harm, routine corticosteroids should be avoided except in specific situations. In general, steroids maybe avoided as first line drugs in newly diagnosed IBD patients [12].…”

Section: Corticosteroidsmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 in patients with inflammatory bowel disease

Anikhindi

Kumar

Arora

2020

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Introduction: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread world over causing morbidity and mortality in affected patients, especially elderly and those with co-morbidities. Inflammatory Bowel Disease (IBD) patients frequently require immunosuppressive therapy and are known to be at risk of opportunistic infections. Areas covered: We hereby review the available literature pertaining to COVID-19 in IBD based on published consensus guidelines, expert opinions, case series, registries and reports. Expert opinion: Preliminary data suggests no increase in incidence of COVID-19 in IBD patients as compared to general population. Morbidity and mortality rates attributable to COVID-19 are also similar in IBD patients as compared to general population. Though exact reason is unknown, some aspects of COVID-19 pathogenesis may explain this paradox. Medications for IBD need to be carefully reviewed during COVID-19 crisis. Steroids may need dose tapering or substitution to avoid complications based on anecdotal evidence. Endoscopic procedures for IBD maybe deferred unless absolutely necessary. General measures recommended for COVID-19 tailored to specific needs of IBD patients maybe the best way to prevent infection. Our understanding of the disease outcomes and optimal management protocols are likely to evolve as we move ahead in this pandemic.

show abstract

Section: Covid-19 In Ibd: Clinical Featuresmentioning

confidence: 99%

Section: Corticosteroidsmentioning

confidence: 99%

COVID-19 in patients with inflammatory bowel disease

Anikhindi

Kumar

Arora

2020

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

show abstract

“…The various society guidelines (Asian-Pacific Association of Gastroenterology IBD group [58], European Society for Pediatric Gastroenterology Hepatology and Nutrition [59], European Crohn's and Colitis Organization [60], Bristish Society of Gastroenterology [61], Crohn's and Colitis Foundation [62], American Gastroenterological Association [63], World Endoscopy Organization [64]) have been enlisted in Supplementary Table 2 and a summary of the recommendations for IBD management during the COVID-19 pandemic have been outlined in Appendix Panel 2.…”

Section: Covid-19 and Ibdmentioning

confidence: 99%

Corona Virus Disease-19 pandemic: The gastroenterologists’ perspective

Dhar

Samanta

Kochhar

2020

Indian J Gastroenterol

View full text Add to dashboard Cite

The world is witnessing a serious public health threat in the wake of the third corona virus pandemic, a novel corona virus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]). The Corona Virus Disease-19 (COVID-19) is not limited to the respiratory system but has widespread involvement including the gastrointestinal (GI) tract and liver, with evidence of prolonged fecal shedding and feco-oral transmission. This finding has stirred up a hornet's nest of not only a newer modality of the spread of the virus but also a risk of the unpredictable duration of the infective potential of the shedders. We reviewed the literature on fecal shedding and possible implications on prevention and surveillance strategies. The pandemic is changing the management of underlying chronic diseases such as inflammatory bowel disease (IBD) and other diseases. Moreover, for the gastroenterologist, doing endoscopic procedures in this COVID-19 era poses a high risk of contamination, as it is an aerosol-generating procedure. There is a daily influx of data on this disease, and multiple societies are coming up with various recommendations. We provide a comprehensive review of all the reported GI manifestations of COVID-19 infection and the side effects of confounding drugs. We have summarized the management recommendations for diseases such as IBD with COVID-19 and nutritional recommendations and provided a concise review of the endoscopy guidelines by the various societies. This review provides a comprehensive account and a lucid guide covering various aspects of gastroenterology practice during this COVID-19 pandemic.

show abstract

“…Alternatively, endoscopic examinations of patients with COVID-19 can be performed in operating theatres (with negative pressure). Some professional societies and authors have already addressed the question of how to proceed with endoscopic examinations after the pandemic [90][91][92]. Most favour a risk-adapted, gradual return to normal operation ("new normal").…”

Section: Recommendation Level: El5/consensus Level: Strong Consensus mentioning

confidence: 99%

Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers

et al. 2020

View full text Add to dashboard Cite

The COVID-19 pandemic is a global outbreak of new onset infections with the SARS-CoV-2 virus. To date, more than 3.4 million people have been infected throughout the world. In Germany, approximately 450,000 patients suffer from inflammatory bowel disease; these patients generally require continuous expert care and support. Against the background of a rapidly accumulating knowledge base on SARS-CoV-2, 68 expert authors of the current DGVS guidelines for Crohn’s disease and ulcerative colitis took part in a virtual meeting to compile up-to-date, practice-orientated recommendations aimed at improving the care of patients with IBD. These recommendations address the risk of infection, including the risk for specific patient groups, the possible course of the disease, and consequences for pharmacological and surgical therapies of the underlying disease, as well as general measures for infection prevention and adjuvant prophylactic and therapeutic options.

show abstract

Practical advice for management of inflammatory bowel diseases patients during the COVID‐19 pandemic: World Endoscopy Organization Statement

Cited by 12 publications

References 23 publications

COVID-19 in patients with inflammatory bowel disease

COVID-19 in patients with inflammatory bowel disease

Corona Virus Disease-19 pandemic: The gastroenterologists’ perspective

Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers

Contact Info

Product

Resources

About